azacitidine and Joint Pain

azacitidine has been researched along with Joint Pain in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Alvarado, Y; Andreeff, M; Borthakur, G; Bose, P; Chien, KS; Cortes, JE; Daver, NG; DiNardo, CD; Dong, XQ; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Kim, K; Klingner-Winton, C; Montalban-Bravo, G; Naqvi, K; Nogueras-Gonzalez, GM; Pierce, SA; Sheppard, KB; Soltysiak, KA	1

Trials

1 trial(s) available for azacitidine and Joint Pain

Article	Year
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. British journal of haematology, 2021, Volume: 195, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites; Arthralgia; Azacitidine; Constipation; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Pneumonia; Programmed Cell Death 1 Receptor; Progression-Free Survival; Risk	2021

Article

Year

Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.

British journal of haematology, 2021, Volume: 195, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites; Arthralgia; Azacitidine; Constipation; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Pneumonia; Programmed Cell Death 1 Receptor; Progression-Free Survival; Risk

2021